VOR BIOPHARMA INC.
VORLoading price...
Overview
Previous Close--
Open--
Ask--
Bid--
Day's Range -
52 Week Range -
PE Ratio(TTM)--
Market Cap--
Volume--
Avg. Volume--
12 Months Earnings-883.08M
12 Months Revenue0.00
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 373.51M | 371.64M | 121.19M | 126.04M | 93.42M |
| Profit after Tax (Net Income) | -883.08M | -695.98M | -116.91M | -117.86M | -92.09M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Boston, United States
Website: https://www.vorbio.com
Chairman, President & CEO: Dr. Jean-Paul Kress M.D.
Employees: 76
About Company:
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.